

**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1-96. (Cancelled).

97. (Currently Amended) An isolated antibody that immunospecifically binds BLySB Lymphocyte Stimulator protein which comprises a first amino acid sequence at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 and a second amino acid sequence at least 85% identical to amino acid residues ~~139~~141-249 of SEQ ID NO:327 wherein said B Lymphocyte Stimulator protein is selected from the group consisting of:

(a) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;

(b) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228; and

(c) a trimer of the protein of (b).

98. (Currently Amended) The antibody of claim 97 wherein the first amino acid sequence is at least 95% identical to amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence is at least 95% identical to amino acid residues ~~139~~141-249 of SEQ ID NO:327.

99. (Currently Amended) The antibody of claim 97 wherein the amino acid differences between the first amino acid sequence and amino acid residues 1-123 of SEQ ID NO:327 are in one or more of the CDR regions located at amino acid residues 26-35, 50-66 and 99-112 of SEQ ID NO: 327 and wherein the amino acid differences between the second amino acid sequence and amino acid residues ~~139~~141-249 of SEQ ID NO: 327 are in one or more of the CDR regions located at amino acid residues 163-173, 189-195 and 228-238 of SEQ ID NO: 327.

100. (Currently Amended) An isolated antibody that immunospecifically binds B Lymphocyte Stimulator protein which comprises ~~The antibody of claim 97 wherein the first amino acid sequence is amino acid residues 1-123 of SEQ ID NO: 327 and the second amino acid sequence is amino acid residues 139141-249 of SEQ ID NO: 327~~ wherein said B Lymphocyte Stimulator protein is selected from the group consisting of:

(a) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;

(b) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228; and

(c) a trimer of the protein of (b).

101-118. (Cancelled).

119. (Previously Presented) The antibody of claim 97 wherein the antibody is selected from the group consisting of:

- (a) a whole immunoglobulin molecule;
- (b) an scFv;
- (c) a chimeric antibody;
- (d) a Fab fragment;
- (e) an Fab' fragment; and
- (f) an F(ab')<sub>2</sub>.

120. (Previously Presented) The antibody of claim 97 wherein the antibody is a monoclonal antibody.

121. (Previously Presented) The antibody of claim 97 wherein the antibody is a human antibody.

122. (Previously Presented) The antibody of claim 97 which comprises a heavy chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human IgM constant domain;
- (b) a human IgG1 constant domain;
- (c) a human IgG2 constant domain;

- (d) a human IgG3 constant domain;
- (e) a human IgG4 constant domain; and
- (f) a human IgA constant domain.

123. (Previously Presented) The antibody of claim 97 which comprises a light chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human kappa constant domain; and
- (b) a human lambda constant domain.

124. (Previously Presented) The antibody of claim 97 wherein the antibody has a dissociation constant ( $K_D$ ) less than or equal to  $10^{-9}$ M.

125. (Previously Presented) The antibody of claim 97 wherein the antibody is coupled to a detectable label.

126. (Previously Presented) The antibody of claim 125 wherein the detectable label is a radioisotope, an enzyme, a fluorescent label, a luminescent label, bioluminescent label or biotin.

127. (Previously Presented) The antibody of claim 126 wherein the radioisotope is  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{90}\text{Y}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{177}\text{Lu}$ ,  $^{166}\text{Ho}$ , or  $^{153}\text{Sm}$ .

128-129. (Cancelled).

130. (Currently Amended) The antibody of claim 97 wherein the antibody neutralizes ~~BLyS~~said protein.

131. (Currently Amended) The antibody of claim 130 wherein the antibody diminishes the ability of ~~BLyS~~said protein to bind to a ~~BLyS~~receptor of said protein.

132. (Currently Amended) The antibody of claim 131 wherein the ~~BLyS~~ receptor is TACI.

133. (Currently Amended) The antibody of claim 131 wherein the ~~BLyS~~ receptor is BCMA.

134. (Currently Amended) The antibody of claim 130 wherein the antibody diminishes the ability of ~~BLyS~~ said protein to stimulate B cell proliferation.

135. (Currently Amended) The antibody of claim 130 wherein the antibody diminishes the ability of said protein ~~BLyS~~ to stimulate immunoglobulin secretion by B cells.

136. (Previously Presented) The antibody of claim 100 wherein the antibody is selected from the group consisting of:

- (a) a whole immunoglobulin molecule;
- (b) an scFv;
- (c) a chimeric antibody;
- (d) a Fab fragment;
- (e) an Fab' fragment; and
- (f) an F(ab')<sub>2</sub>.

137. (Previously Presented) The antibody of claim 100 wherein the antibody is a monoclonal antibody.

138. (Previously Presented) The antibody of claim 100 wherein the antibody is a human antibody.

139. (Previously Presented) The antibody of claim 100 which comprises a heavy chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human IgM constant domain;
- (b) a human IgG1 constant domain;
- (c) a human IgG2 constant domain;
- (d) a human IgG3 constant domain;
- (e) a human IgG4 constant domain; and
- (f) a human IgA constant domain.

140. (Previously Presented) The antibody of claim 100 which comprises a light chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human kappa constant domain; and
- (b) a human lambda constant domain.

141. (Previously Presented) The antibody of claim 100 wherein the antibody is coupled to a detectable label.

142. (Previously Presented) The antibody of claim 141 wherein the detectable label is a radioisotope, an enzyme, a fluorescent label, a luminescent label, bioluminescent label or biotin.

143. (Previously Presented) The antibody of claim 142 wherein the radioisotope is  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{90}\text{Y}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{177}\text{Lu}$ ,  $^{166}\text{Ho}$ , or  $^{153}\text{Sm}$ .

144. (Currently Amended) An antibody purified from the cell line contained in ATCC<sup>TM</sup> Deposit Number PTA-3239.

145. (Currently Amended) An antibody purified from the cell line contained in ATCC<sup>TM</sup> Deposit Number PTA-3240.

146. (New) The antibody of claim 100 which comprises a human IgG1 heavy chain immunoglobulin constant domain and a human lambda light chain immunoglobulin constant domain.

147. (New) The antibody of claim 100 wherein the antibody neutralizes said protein.

148. (New) The antibody of claim 147 wherein the antibody diminishes the ability of said protein to bind to a receptor of said protein.

149. (New) The antibody of claim 148 wherein the receptor is TACI.

150. (New) The antibody of claim 148 wherein the receptor is BCMA.

151. (New) The antibody of claim 147 wherein the antibody diminishes the ability of said protein to stimulate B cell proliferation.

152. (New) The antibody of claim 147 wherein the antibody diminishes the ability of said protein to stimulate immunoglobulin secretion by B cells.